23Andme Holding Co (ME) Stock
ME is no longer traded. 23Andme Holding was delisted from the Nasdaq in March 2025.
Prices on this page are historical; the last trade was March 28, 2025 at $0.61.
23Andme Holding stock price history
ME final trading statistics
- Final close
- $0.61
- Final trading day
- Mar 28, 2025
- Market cap at delisting
- $11.96M
- Shares outstanding
- 19.72M
- Final 52-week range
- $0.26 – $5.50
- Avg. volume (final 3 mo.)
- 3,930,992
- All-time high (split-adj.)
- $353.00 · Feb 2021
- All-time low (split-adj.)
- $0.53 · Mar 2025
- Return since IPO
- -99.7%
- Beta
- 1.20
- Book value / share
- $2.35
- Price / book
- 0.26
23Andme Holding annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $219.64M | -$666.7M | -$0.66 |
| FY2023 | $299.49M | -$311.7M | -$0.51 |
| FY2022 | $271.89M | -$217.5M | -$0.70 |
| FY2021 | $243.92M | -$183.4M | -$1.93 |
| FY2020 | $305.46M | -$289.3M | -$0.38 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About 23Andme Holding Co
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. The company has collaboration with Mirador Therapeutics to advance mirador's precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California. On March 23, 2025, 23andMe Holding Co., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Missouri.
23Andme Holding stock FAQ
What happened to 23Andme Holding stock?
23Andme Holding stock was delisted from the Nasdaq. Its final close was $0.61 on March 28, 2025.
Is ME stock still trading?
No. ME was delisted from the Nasdaq in March 2025 and no longer trades on a U.S. exchange.
What was the last price of ME stock?
ME closed at $0.61 on its final trading day, March 28, 2025, for a market value of about $11.96M.
What were 23Andme Holding's revenue and earnings in its last full fiscal year?
23Andme Holding reported revenue of $219.64M and net income of -$666.7M in fiscal 2024, its last full year as a public company.
When did 23Andme Holding go public?
23Andme Holding Co stock began trading on November 23, 2020.